Selected research
Industry Research
Untargeted Metabolomics Industry Research Report 2026
Market perspective
The global Untargeted Metabolomics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Untargeted Metabolomics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Untargeted Metabolomics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Untargeted Metabolomics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Untargeted Metabolomics include Creative Proteomics, Metabolon, Alfa Chemistry, Novelgene Technologies, MtoZ-Biolabs Inc., CD Genomics, Metware Biotechnology Inc (Metware), BGI Genomics and APPLIED PROTEIN TECHNOLOGY, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Untargeted Metabolomics market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Untargeted Metabolomics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Untargeted Metabolomics Market by Company
Creative Proteomics
Metabolon
Alfa Chemistry
Novelgene Technologies
MtoZ-Biolabs Inc.
CD Genomics
Metware Biotechnology Inc (Metware)
BGI Genomics
APPLIED PROTEIN TECHNOLOGY
Suzhou PANOMIX Biomedical Tech Co.,Ltd
OBiO Technology ( Shanghai ) Corp.,Ltd.
Beijing Huayi innovation & BioTechnology Co., Ltd
Abace Biotechnology
Metabo-Profile
Untargeted Metabolomics Segment by Type
Plant Untargeted Metabolomics
Human Untargeted Metabolomics
Other
Untargeted Metabolomics Segment by Application
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Untargeted Metabolomics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Untargeted Metabolomics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Untargeted Metabolomics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Untargeted Metabolomics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Untargeted Metabolomics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Plant Untargeted Metabolomics
- Human Untargeted Metabolomics
- Other
Applications
- Academic and Research Institutions
- Pharmaceutical and Biotechnology Companies
Companies covered
- Creative Proteomics
- Metabolon
- Alfa Chemistry
- Novelgene Technologies
- MtoZ-Biolabs Inc.
- CD Genomics
- Metware Biotechnology Inc (Metware)
- BGI Genomics
- APPLIED PROTEIN TECHNOLOGY
- Suzhou PANOMIX Biomedical Tech Co.,Ltd
- OBiO Technology ( Shanghai ) Corp.,Ltd.
- Beijing Huayi innovation & BioTechnology Co., Ltd
- Abace Biotechnology
- Metabo-Profile
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Untargeted Metabolomics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Plant Untargeted Metabolomics
- 2.2.3 Human Untargeted Metabolomics
- 2.2.4 Other
- 2.3 Untargeted Metabolomics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Academic and Research Institutions
- 2.3.3 Pharmaceutical and Biotechnology Companies
- 2.4 Assumptions and Limitations
3 Untargeted Metabolomics Breakdown Data by Type
- 3.1 Global Untargeted Metabolomics Historic Market Size by Type (2021-2026)
- 3.2 Global Untargeted Metabolomics Forecasted Market Size by Type (2027-2032)
4 Untargeted Metabolomics Breakdown Data by Application
- 4.1 Global Untargeted Metabolomics Historic Market Size by Application (2021-2026)
- 4.2 Global Untargeted Metabolomics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Untargeted Metabolomics Market Perspective (2021-2032)
- 5.2 Global Untargeted Metabolomics Growth Trends by Region
- 5.2.1 Global Untargeted Metabolomics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Untargeted Metabolomics Historic Market Size by Region (2021-2026)
- 5.2.3 Untargeted Metabolomics Forecasted Market Size by Region (2027-2032)
- 5.3 Untargeted Metabolomics Market Dynamics
- 5.3.1 Untargeted Metabolomics Industry Trends
- 5.3.2 Untargeted Metabolomics Market Drivers
- 5.3.3 Untargeted Metabolomics Market Challenges
- 5.3.4 Untargeted Metabolomics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Untargeted Metabolomics Players by Revenue
- 6.1.1 Global Top Untargeted Metabolomics Players by Revenue (2021-2026)
- 6.1.2 Global Untargeted Metabolomics Revenue Market Share by Players (2021-2026)
- 6.2 Global Untargeted Metabolomics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Untargeted Metabolomics Head Office and Area Served
- 6.4 Global Untargeted Metabolomics Players, Product Type & Application
- 6.5 Global Untargeted Metabolomics Manufacturers Established Date
- 6.6 Global Untargeted Metabolomics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Untargeted Metabolomics Market Size (2021-2032)
- 7.2 North America Untargeted Metabolomics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Untargeted Metabolomics Market Size by Country (2021-2026)
- 7.4 North America Untargeted Metabolomics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Untargeted Metabolomics Market Size (2021-2032)
- 8.2 Europe Untargeted Metabolomics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Untargeted Metabolomics Market Size by Country (2021-2026)
- 8.4 Europe Untargeted Metabolomics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Untargeted Metabolomics Market Size (2021-2032)
- 9.2 Asia-Pacific Untargeted Metabolomics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Untargeted Metabolomics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Untargeted Metabolomics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Untargeted Metabolomics Market Size (2021-2032)
- 10.2 South America Untargeted Metabolomics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Untargeted Metabolomics Market Size by Country (2021-2026)
- 10.4 South America Untargeted Metabolomics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Untargeted Metabolomics Market Size (2021-2032)
- 11.2 Middle East & Africa Untargeted Metabolomics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Untargeted Metabolomics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Untargeted Metabolomics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Creative Proteomics
- 12.1.1 Creative Proteomics Company Information
- 12.1.2 Creative Proteomics Business Overview
- 12.1.3 Creative Proteomics Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.1.4 Creative Proteomics Untargeted Metabolomics Product Portfolio
- 12.1.5 Creative Proteomics Recent Developments
- 12.2 Metabolon
- 12.2.1 Metabolon Company Information
- 12.2.2 Metabolon Business Overview
- 12.2.3 Metabolon Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.2.4 Metabolon Untargeted Metabolomics Product Portfolio
- 12.2.5 Metabolon Recent Developments
- 12.3 Alfa Chemistry
- 12.3.1 Alfa Chemistry Company Information
- 12.3.2 Alfa Chemistry Business Overview
- 12.3.3 Alfa Chemistry Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.3.4 Alfa Chemistry Untargeted Metabolomics Product Portfolio
- 12.3.5 Alfa Chemistry Recent Developments
- 12.4 Novelgene Technologies
- 12.4.1 Novelgene Technologies Company Information
- 12.4.2 Novelgene Technologies Business Overview
- 12.4.3 Novelgene Technologies Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.4.4 Novelgene Technologies Untargeted Metabolomics Product Portfolio
- 12.4.5 Novelgene Technologies Recent Developments
- 12.5 MtoZ-Biolabs Inc.
- 12.5.1 MtoZ-Biolabs Inc. Company Information
- 12.5.2 MtoZ-Biolabs Inc. Business Overview
- 12.5.3 MtoZ-Biolabs Inc. Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.5.4 MtoZ-Biolabs Inc. Untargeted Metabolomics Product Portfolio
- 12.5.5 MtoZ-Biolabs Inc. Recent Developments
- 12.6 CD Genomics
- 12.6.1 CD Genomics Company Information
- 12.6.2 CD Genomics Business Overview
- 12.6.3 CD Genomics Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.6.4 CD Genomics Untargeted Metabolomics Product Portfolio
- 12.6.5 CD Genomics Recent Developments
- 12.7 Metware Biotechnology Inc (Metware)
- 12.7.1 Metware Biotechnology Inc (Metware) Company Information
- 12.7.2 Metware Biotechnology Inc (Metware) Business Overview
- 12.7.3 Metware Biotechnology Inc (Metware) Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.7.4 Metware Biotechnology Inc (Metware) Untargeted Metabolomics Product Portfolio
- 12.7.5 Metware Biotechnology Inc (Metware) Recent Developments
- 12.8 BGI Genomics
- 12.8.1 BGI Genomics Company Information
- 12.8.2 BGI Genomics Business Overview
- 12.8.3 BGI Genomics Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.8.4 BGI Genomics Untargeted Metabolomics Product Portfolio
- 12.8.5 BGI Genomics Recent Developments
- 12.9 APPLIED PROTEIN TECHNOLOGY
- 12.9.1 APPLIED PROTEIN TECHNOLOGY Company Information
- 12.9.2 APPLIED PROTEIN TECHNOLOGY Business Overview
- 12.9.3 APPLIED PROTEIN TECHNOLOGY Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.9.4 APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Product Portfolio
- 12.9.5 APPLIED PROTEIN TECHNOLOGY Recent Developments
- 12.10 Suzhou PANOMIX Biomedical Tech Co.,Ltd
- 12.10.1 Suzhou PANOMIX Biomedical Tech Co.,Ltd Company Information
- 12.10.2 Suzhou PANOMIX Biomedical Tech Co.,Ltd Business Overview
- 12.10.3 Suzhou PANOMIX Biomedical Tech Co.,Ltd Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.10.4 Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Product Portfolio
- 12.10.5 Suzhou PANOMIX Biomedical Tech Co.,Ltd Recent Developments
- 12.11 OBiO Technology ( Shanghai ) Corp.,Ltd.
- 12.11.1 OBiO Technology ( Shanghai ) Corp.,Ltd. Company Information
- 12.11.2 OBiO Technology ( Shanghai ) Corp.,Ltd. Business Overview
- 12.11.3 OBiO Technology ( Shanghai ) Corp.,Ltd. Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.11.4 OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Product Portfolio
- 12.11.5 OBiO Technology ( Shanghai ) Corp.,Ltd. Recent Developments
- 12.12 Beijing Huayi innovation & BioTechnology Co., Ltd
- 12.12.1 Beijing Huayi innovation & BioTechnology Co., Ltd Company Information
- 12.12.2 Beijing Huayi innovation & BioTechnology Co., Ltd Business Overview
- 12.12.3 Beijing Huayi innovation & BioTechnology Co., Ltd Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.12.4 Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Product Portfolio
- 12.12.5 Beijing Huayi innovation & BioTechnology Co., Ltd Recent Developments
- 12.13 Abace Biotechnology
- 12.13.1 Abace Biotechnology Company Information
- 12.13.2 Abace Biotechnology Business Overview
- 12.13.3 Abace Biotechnology Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.13.4 Abace Biotechnology Untargeted Metabolomics Product Portfolio
- 12.13.5 Abace Biotechnology Recent Developments
- 12.14 Metabo-Profile
- 12.14.1 Metabo-Profile Company Information
- 12.14.2 Metabo-Profile Business Overview
- 12.14.3 Metabo-Profile Revenue in Untargeted Metabolomics Business (2021-2026)
- 12.14.4 Metabo-Profile Untargeted Metabolomics Product Portfolio
- 12.14.5 Metabo-Profile Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst